- Investing Ideas
- U.S. Pharmaceuticals & Biotech Top Growth Stocks
U.S. Pharmaceuticals & Biotech Top Growth Stocks
Results
40
40 companies
Axsome Therapeutics
Market Cap: US$8.1b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$156.92
7D
0.5%
1Y
23.8%
Madrigal Pharmaceuticals
Market Cap: US$10.4b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$441.16
7D
-0.8%
1Y
29.1%
Travere Therapeutics
Market Cap: US$2.5b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$26.84
7D
-3.5%
1Y
30.7%
Zevra Therapeutics
Market Cap: US$541.9m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$9.23
7D
-7.5%
1Y
15.2%
Syndax Pharmaceuticals
Market Cap: US$2.1b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$24.23
7D
3.1%
1Y
76.7%
Insmed
Market Cap: US$31.0b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$136.00
7D
-2.5%
1Y
70.2%
Marker Therapeutics
Market Cap: US$22.3m
A clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States.
MRKR
US$1.34
7D
0.8%
1Y
7.2%
Rhythm Pharmaceuticals
Market Cap: US$6.0b
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally.
RYTM
US$87.45
7D
0.08%
1Y
68.0%
Ardelyx
Market Cap: US$1.3b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$5.31
7D
-8.1%
1Y
3.5%
ARS Pharmaceuticals
Market Cap: US$819.2m
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally.
SPRY
US$8.17
7D
-2.6%
1Y
-33.9%
Pelthos Therapeutics
Market Cap: US$74.3m
A bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
PTHS
US$20.74
7D
-15.3%
1Y
32.1%
Achieve Life Sciences
Market Cap: US$217.7m
A late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
ACHV
US$4.00
7D
-4.1%
1Y
42.3%
Capricor Therapeutics
Market Cap: US$1.8b
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$29.10
7D
-4.6%
1Y
126.3%
Corcept Therapeutics
Market Cap: US$3.6b
A biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
CORT
US$34.64
7D
7.7%
1Y
-40.9%
AC Immune
Market Cap: US$292.6m
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
ACIU
US$2.85
7D
-5.5%
1Y
35.7%
Kiniksa Pharmaceuticals International
Market Cap: US$3.5b
A biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
KNSA
US$46.08
7D
0.7%
1Y
97.3%
CollPlant Biotechnologies
Market Cap: US$8.8m
A regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally.
CLGN
US$0.61
7D
5.1%
1Y
-80.2%
CG Oncology
Market Cap: US$5.6b
A late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
CGON
US$65.08
7D
1.2%
1Y
140.6%
Arcutis Biotherapeutics
Market Cap: US$2.8b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$22.21
7D
-2.4%
1Y
30.6%
Viridian Therapeutics
Market Cap: US$2.8b
Engages in discovering, developing, and commercializing treatments for serious and rare diseases.
VRDN
US$26.98
7D
-5.9%
1Y
76.8%
Invivyd
Market Cap: US$409.8m
Engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States.
IVVD
US$1.38
7D
-20.7%
1Y
87.0%
Verrica Pharmaceuticals
Market Cap: US$99.6m
A dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States.
VRCA
US$5.45
7D
-10.8%
1Y
-2.3%
Belite Bio
Market Cap: US$6.3b
A clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States.
BLTE
US$154.59
7D
-5.8%
1Y
129.8%
SIGA Technologies
Market Cap: US$364.0m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$4.94
7D
-6.1%
1Y
-11.9%
Unicycive Therapeutics
Market Cap: US$146.4m
A clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States.
UNCY
US$6.73
7D
-1.5%
1Y
-1.0%
BeOne Medicines
Market Cap: US$31.3b
An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
ONC
US$275.28
7D
-3.1%
1Y
9.2%
Praxis Precision Medicines
Market Cap: US$8.3b
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.
PRAX
US$298.31
7D
1.5%
1Y
703.6%
Krystal Biotech
Market Cap: US$7.5b
A commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States.
KRYS
US$251.68
7D
1.8%
1Y
34.5%
Journey Medical
Market Cap: US$231.1m
Focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
DERM
US$6.63
7D
-8.2%
1Y
15.5%
Mirum Pharmaceuticals
Market Cap: US$5.5b
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
MIRM
US$88.51
7D
-2.4%
1Y
88.2%
Amicus Therapeutics
Market Cap: US$4.5b
A biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally.
FOLD
US$14.43
7D
0.4%
1Y
60.2%
Benitec Biopharma
Market Cap: US$393.9m
A clinical-stage biotechnology company, focuses on the development of novel genetic medicines.
BNTC
US$10.98
7D
-6.6%
1Y
-31.8%
Fortress Biotech
Market Cap: US$97.5m
A biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products.
FBIO
US$2.99
7D
-3.5%
1Y
74.9%
Arcellx
Market Cap: US$6.7b
Together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States.
ACLX
US$114.77
7D
0.3%
1Y
65.5%
Prelude Therapeutics
Market Cap: US$246.8m
A clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.
PRLD
US$2.99
7D
-9.4%
1Y
320.8%
Geron
Market Cap: US$992.8m
A commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology.
GERN
US$1.46
7D
-7.6%
1Y
-19.8%